June 17, 2022

Skyrizi® (risankizumab-rzaa – AbbVie) is now the first and only specific interleukin-23 (IL23) inhibitor to receive FDA approval for treating moderately to severely active Crohn’s disease in adults.

  • First FDA approved in 2019, Skyrizi is also indicated to treat active psoriatic arthritis and moderate to severe plaque psoriasis.
  • The recommended starting dose for Crohn’s disease is 600mg administered by intravenous infusion at Weeks 0, 4, and 8 of treatment. Maintenance treatment begins at Week 12, with a recommended dose of 360mg administered by subcutaneous injection once every eight weeks.

 

July 31, 2022

Brand Medications with Generic Alternatives Anticipated to be Approved in August

Read More
July 19, 2022

FDA Approves First Therapy for Repigmentation in Vitiligo

Read More
July 15, 2022

Zonisade Approved to Treat Seizures

Read More
July 14, 2022

Xalkori Granted New Indication to Treat Non-Cancerous Tumors

Read More